Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults

Stephanie R. Rainey-Smith1,2, Belinda M. Brown1,2, Hamid R. Sohrabi1,2,5, Tejal Shah1,2, Kathryn G. Goozee3,4, Veer B. Gupta1,2 and Ralph N. Martins1,2,3*

1School of Medical and Health Sciences, Centre of Excellence for Alzheimer’s Disease Research & Care, Edith Cowan University, Joondalup, WA 6027, Australia
2Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital), Perth, WA 6009, Australia
3School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, WA 6009, Australia
4Mcusker KAVLIA Research Centre, Anglican Retirement Villages, Sydney, NSW 2229, Australia

(Submitted 14 November 2015 – Final revision received 19 February 2016 – Accepted 2 March 2016 – First published online 22 April 2016)

Abstract
Curcumin therapy in animals has produced positive cognitive and behavioural outcomes; results of human trials, however, have been inconsistent. In this study, we report the results of a 12-month, randomised, placebo-controlled, double-blind study that investigated the ability of a curcumin formulation to prevent cognitive decline in a population of community-dwelling older adults. Individuals (n 96) ingested either placebo or 1500 mg/d BiocurcumaxTM for 12 months. A battery of clinical and cognitive measures was administered at baseline and at the 6-month and 12-month follow-up assessments. A significant time × treatment group interaction was observed for the Montreal Cognitive Assessment (repeated-measures analysis; time × treatment; F=3.85, P<0.05). Subsequent analysis revealed that this association was driven by a decline in function of the placebo group at 6 months that was not observed in the curcumin treatment group. No differences were observed between the groups for all other clinical and cognitive measures. Our findings suggest that further longitudinal assessment is required to investigate changes in cognitive outcome measures, ideally in conjunction with biological markers of neurodegeneration.

Key words: Curcumin; Cognition; Ageing; Alzheimer’s disease

The phytochemical curcumin, derived from the rhizome of Curcuma longa, is a constituent of the widely used spice turmeric(1,2). Curcumin has been extensively reported to demonstrate many beneficial biological effects including anti-cancer, antioxidant and anti-inflammatory activities(2–5). In addition to these properties, both in vitro and in vivo studies have shown that curcumin can bind to the proteins β amyloid (Aβ) and tau as well as inhibit Aβ aggregation and modulate tau processing(6–9). Such characteristics are highly desirable, given that cerebral accumulation of Aβ aggregates and intra-neuronal deposits of insoluble hyperphosphorylated tau are pathological hallmarks of Alzheimer’s disease (AD)(10,11), whereas both oxidative stress and inflammation are heavily implicated in AD pathogenesis(12–14).

A recent in vitro study has demonstrated that curcumin can induce structural changes in Aβ aggregates, which likely attenuate Aβ-induced toxicity(15). Moreover, several in vivo studies have shown that dietary curcumin crosses the blood–brain barrier and subsequently decreases Aβ deposition and plaque load in the brain of transgenic mouse models of AD(16–18). Additional transgenic mouse studies have demonstrated marked inhibition of tau phosphorylation(19), reduced soluble tau and elevated levels of molecular chaperones (heat shock proteins) involved in tau degradation(20) following curcumin therapy. These Aβ- and tau-modifying attributes, as well as its anti-inflammatory and antioxidant properties, in combination with an excellent safety profile, have helped make curcumin an appealing target for studies aimed at developing AD prevention and intervention strategies.

Indeed, investigations of the effect of curcumin therapy on cognition and behaviour in animals have revealed positive functional outcomes. Pre-treatment with dietary curcumin, at a dose of 500 parts per million (ppm) for 2 months, prevented Aβ infusion-induced spatial memory de

**Abbreviations:** Aβ, β-amyloid; AD, Alzheimer’s disease; MoCA, Montreal Cognitive Assessment.

* Corresponding author: Professor R. N. Martins, fax +61 8 9347 4299, email ralph.n.martins@gmail.com
human studies. An epidemiological study reported better global cognition, as determined by the Mini-Mental State Examination (MMSE) score, among elderly Singaporean individuals consuming higher levels of curcumin in the form of curry compared with those who ‘never or rarely’ consume curcumin\(^{21}\).

Two subsequent 6-month, randomised, placebo-controlled, double-blinded studies conducted in early-to-moderate AD patients found curcumin formulations to be well tolerated and safe; however, no differences in measures were observed between treatment groups\(^{22,23}\). The outcome measures included MMSE, the Alzheimer’s Disease Assessment Scale, cognitive sub-section, the Alzheimer’s Disease Cooperative Study Activities of Daily Living and blood Aβ42, as well as cerebrospinal fluid levels of Aβ42 and tau species. The authors listed limited bioavailability of curcumin (due to dose or formulation), short duration of the studies and the fact that these trials were conducted on individuals already diagnosed with AD in whom cerebral pathology would be considerably advanced as possible explanations for the lack of significant results.

In contrast, a recent 4-week, randomised, placebo-controlled, double-blinded study of sixty healthy adults aged 60–85 years showed improved working memory and mood in the curcumin treatment group. Evaluation of the acute effects of curcumin treatment also revealed improved performance on tasks of working memory and attention compared with placebo as early as 1 h after ingestion\(^{24}\). Participants in the curcumin group received a single daily dose of 400 mg Longvida\(^{®}\) Optimized Curcumin (Verdure Sciences) – a formulation with previously demonstrated bioavailability\(^{25,26}\). Whether the observed beneficial effects of curcumin persist longitudinally, however, remains to be determined.

To date, no longitudinal assessment of the effect of curcumin on cognition in a population of aged community-dwelling cognitively healthy individuals has been undertaken. Consequently, the aim of the present study was to conduct a 12-month, randomised, placebo-controlled, double-blinded study in order to investigate the ability of the curcumin formulation Biocurcumax\(^{TM}\) (Arjuna Natural Extracts Ltd) to prevent cognitive decline in a population of community-dwelling older adults. Cognitively healthy older adults were recruited as they represent a population both at risk of developing clinical AD, yet in whom the preclinical disease stage is believed to be early enough to still be responsive to intervention\(^{27}\). The curcumin formulation Biocurcumax\(^{TM}\) was selected based on its enhanced oral bioavailability; after ingestion of 2 g Biocurcumax\(^{TM}\), a plasma curcumin concentration of 300 ng/g is reached\(^{28}\); however, participants of the present study were given a dose of 1.5 g.

Methods

Participants

In all, 160 community-dwelling older adults were enrolled in to the study at the McCusker Alzheimer’s Research Foundation, Western Australia. Inclusion criteria were as follows: age 40–90 years, with good health and no significant cerebral vascular disease; no significant cognitive impairments as indicated by the Informant Questionnaire on Cognitive Decline in the Elderly or by objective memory assessment measures; normal general cognitive function as indicated by a Montreal Cognitive Assessment (MoCA) score ≥26; and no or minimal impairment in activities of daily living, as determined by a clinical interview and the 36-Item Short Form Health Survey (SF-36)\(^{29}\). Individuals with a MoCA score of 18–25 were discussed by a team of neuropsychologists, and eligibility was determined on a case-by-case basis following stratification of the MoCA score according to age and education\(^{30}\). Exclusion criteria included the following: the presence of dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition\(^{19}\); previous medical history of stroke; current depressive symptoms based on the Depression Anxiety Stress Scales (DASS)\(^{32}\); presence of acute or untreated chronic psychiatric disorders (including drug and alcohol abuse); anti-coagulant or anti-platelet treatment or bleeding risk factors; obstruction of the biliary tract; and non-fluency in English.

This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Human Research Ethics Committee of Hollywood Private Hospital, Western Australia. Written informed consent was obtained from all subjects. The present study is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR; http://www.anzctr.org.au/) under identification number ACTRN12611000437965.

Intervention

This randomised, double-blind, placebo-controlled study was conducted for a period of 12 months. Eligible participants were identified according to age and sex before being randomly assigned into either the curcumin (n 80) or the placebo (n 80) treatment groups. The curcumin group ingested 1×500 mg BCM-95\(^{®}\)CG (Biocurcumax\(^{TM}\)) capsule three times a day (1500 mg/d total), after meals with water. The placebo group ingested 1×placebo capsule three times a day, after meals with water. The placebo (roasted rice powder with no active constituents) and BCM-95\(^{®}\)CG capsules were identical in size and appearance (green-coloured hard gelatin shell of ‘0’ size).

Each BCM-95\(^{®}\)CG capsule contained 88% total curcuminoids (curcumin, bisdemethoxycurcumin, demethoxycurcumin) and 7% volatile oils from rhizomes of C. longa Linn. Participants visited the research centre at 3 monthly intervals to return completed capsule diaries and used capsule bottles and to collect a new capsule diary and the following 3 months’ capsule supply. The completed capsule diaries and a count of returned capsules were used to assess intervention compliance. Only the data of participants reaching an intervention compliance threshold of ≥70% were included in the analysis.

Cognitive and clinical assessment

Comprehensive medical history was captured at baseline by participant self-report, and was subsequently updated at the 6- and 12-month follow-ups. Measurements of blood pressure (mmHg) and weight (kg) were obtained from each participant at baseline and every 3 months thereafter. Pre-morbid verbal...
intelligence was determined at baseline using the Cambridge Contextual Reading Test (13).

Recent mood was assessed by administration of the DASS(34) at baseline and at the 6- and 12-month follow-ups. Participant self-reported assessment of physical and mental health at all time points was obtained using the SF-36(29). The frequency with which participants made errors in prospective as well as retrospective short-term and long-term memory was assessed at baseline and at 6 and 12 months using the sixteen-item self-report Prospective and Retrospective Memory Questionnaire(35).

An array of cognitive measures was administered at baseline and at the 6- and 12-month follow-up assessments. The MoCA was used to assess general cognitive function(36). Verbal learning and memory were examined using the Rey Auditory Verbal Learning Test(37) to provide scores for short-term, long-term and recognition retrieval from memory. Verbal fluency was assessed using the Controlled Oral Word Association Test(38). The Wechsler Digit Symbol Scale from the Wechsler Adult Intelligence Scale revised (WAIS-R)(39) was also administered as a measure of perceptual motor speed. A cognitive composite score (non-computerised) was calculated for each participant by converting the raw scores of the tests listed above to overall sample-based scores, and then averaging the Z scores to compute a single composite score.

The computerised CogState battery (CogState) was also administered to each participant at baseline and at the 6- and 12-month follow-ups. CogState tasks included the following: detection, assessing psychomotor speed; one back task to measure working memory; Groton maze learning (GML) for assessing visual memory. The raw scores of the individual computerised tests were converted to sample-based Z scores, which were then averaged to produce a single computerised composite score.

**APOE genotyping**

Genotyping was conducted on participants’ DNA samples, which had previously been isolated from whole blood samples using a QIAamp DNA Blood Midi Kit (Qiagen) according to the manufacturer’s protocol. APOE genotype was determined through TaqMan® genotyping assays (Life Technologies) for rs7412 (Assay ID C____904973_10) and rs429358 (Assay ID C____3084793_20). TaqMan® assays were performed on a ViiATM 7 real-time PCR system (Applied Biosystems).

**Statistical analysis**

All statistical analyses were performed using IBM SPSS 22 for Windows Vista (SPSS Inc.). A P value of <0.05 determined a significant result for all analyses. Descriptive data analyses (Table 1) were undertaken to provide means, standard deviations and percentages for the treatment and placebo groups. For the evaluation of differences between these groups, independent sample t tests were performed to analyse continuous data and χ² tests to analyse categorical data. Repeated-measures ANCOVA was utilised to measure the effect of treatment on change in all measures from baseline to the 6- and 12-month follow-ups. All models included age, sex, years of education and APOE ε4 allele carriage as covariates. Treatment groups were unblinded following completion of data analysis.

**Results**

A total of 160 participants were enrolled in to the present study; forty-nine participants were excluded before study completion either because of a baseline assessment result that deemed the participant ineligible to remain in the study (six participants), a suspected adverse event (twenty-three participants; gastrointestinal complaints accounted for the majority of adverse events), or because of other personal or medical reasons unrelated to study participation (twenty participants). Furthermore, an additional eight participants were excluded mid-study because of low intervention compliance rates (<70%), and the data of a further seven participants who completed the study were excluded from the analysis because of late-onset intervention non-compliance. Compliance rates were based on returned capsule counts and participant capsule logs; ninety-six participants who met all inclusion, exclusion and compliance criteria were included in the present analysis. Fig. 1 provides a summary of the study cohort at all assessment time points and includes a breakdown of reasons for participant exclusion at each stage.

No differences between the treatment and placebo groups were observed in terms of the demographic and medical history variables evaluated (Table 1). Nevertheless, the placebo group performed significantly better at baseline in the digit symbol task (t = 2.98, P < 0.01), the MoCA (t = 2.10, P < 0.05) and cognitive composite (non-computerised) scores (t = 2.40, P < 0.05), the latter of which was mainly driven by the MoCA and digit symbol scores. As shown in Table 2, there were no significant interactions of time x treatment group for measures of physical health, mental health, mood and self-reported memory function.

Table 3 contains the results of the repeated-measures analysis, evaluating the effect of BCM-95®CG on cognitive performance across the three time-points; baseline, 6 months and 12 months. The time x treatment variable was significant for the MoCA score (time x treatment; F = 3.85, P < 0.05; Table 3 and Fig. 2); however, it is important to note that the time variable itself was not significant (F = 1.64, P = 0.20). Mean MoCA scores improved by 0.64 points in the curcumin group and by 0.09 points in the placebo group from baseline to 12 months (Table 3 and Fig. 2). To assess whether the significant interaction observed in the repeated-measures analysis was driven by the decreased performance of the placebo group at the 6-month follow-up (a result not consistent with the 12-month follow-up assessment; Table 3 and Fig. 2), the analysis was re-run excluding the 6-month MoCA scores for both treatment groups. Using baseline and 12-month MoCA performance only, no significant interaction between time and treatment groups was observed (F = 1.36, P = 0.25; Table 3). No other differences in cognitive test performance were observed across the treatment groups.
Discussion

This study sought to investigate the effect of a 12-month dietary supplementation of curcumin on cognitive function in a cohort of aged, community-dwelling, cognitively healthy individuals. Furthermore, we examined the influence of curcumin on mood and general quality of life. We observed no differences in placebo and treatment groups in changes in cognitive performance from baseline to the 12-month follow-up. However, a significant time x treatment group interaction was observed for the MoCA. Subsequent analysis revealed that this association was driven by a decline in function within the curcumin group.

Table 1. Demographic data of the treatment group and placebo group (Mean values and standard deviations; percentages and numbers)

<table>
<thead>
<tr>
<th></th>
<th>Total (n 96)</th>
<th>Placebo group (n 57)</th>
<th>Curcumin group (n 39)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.0 ± 6.6</td>
<td>65.2 ± 6.1</td>
<td>67.2 ± 7.2</td>
<td>0.15</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>% 70.8</td>
<td>73.7</td>
<td>66.7</td>
<td>0.46</td>
</tr>
<tr>
<td>YOE (years)</td>
<td>14.0 ± 3.5</td>
<td>14.4 ± 3.6</td>
<td>13.4 ± 3.5</td>
<td>0.17</td>
</tr>
<tr>
<td>APOE e4 allele carriage</td>
<td>% 44.8</td>
<td>43.8</td>
<td>46.1</td>
<td>0.82</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.2 ± 4.8</td>
<td>25.8 ± 5.3</td>
<td>26.7 ± 3.9</td>
<td>0.39</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>128.1 ± 18.7</td>
<td>127.6 ± 19.5</td>
<td>128.8 ± 17.8</td>
<td>0.75</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>76.2 ± 11.1</td>
<td>74.9 ± 11.8</td>
<td>78.0 ± 9.9</td>
<td>0.19</td>
</tr>
<tr>
<td>IPAQ (MET-min/week)</td>
<td>4586 ± 3115</td>
<td>4272 ± 2599</td>
<td>5100 ± 3805</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Medical history

| Hypertension             | % 28.1      | 26.3                 | 30.8                  | 0.55 |
|                         | n 27        | 15                   | 12                    |     |
| Depression              | % 22.9      | 24.6                 | 20.5                  | 0.67 |
|                         | n 22        | 14                   | 8                     |     |
| Anxiety                 | % 13.5      | 14.0                 | 12.8                  | 0.95 |
|                         | n 13        | 8                    | 5                     |     |
| CCRT score              | 38.7 ± 5.7  | 39.2 ± 5.7           | 38.1 ± 5.7            | 0.36 |

YOE, years of education; IPAQ, International Physical Activity Questionnaire; MET, metabolic equivalent task; CCRT, Cambridge Contextual Reading Test.

* P values are determined by independent samples t test for continuous variables and χ² test for categorical variables.

Fig. 1. Study participant flow chart. IPB, ineligible post-baseline assessment; AE, suspected adverse event; INC, intervention non-compliance (<70%); other, personal or medical reason(s) unrelated to study participation.
Table 2. Adjusted marginal means of physical health, mental health, mood and self-reported memory function measures at all time points for the treatment group and placebo group (Mean values and standard deviations)

<table>
<thead>
<tr>
<th></th>
<th>Placebo group</th>
<th>Curcumin group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>6 months</td>
</tr>
<tr>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>SF-36 physical health</td>
<td>79.6</td>
<td>2.0</td>
</tr>
<tr>
<td>SF-36 mental health</td>
<td>84.6</td>
<td>1.5</td>
</tr>
<tr>
<td>DASS – depression</td>
<td>2.71</td>
<td>0.80</td>
</tr>
<tr>
<td>DASS – anxiety</td>
<td>2.63</td>
<td>0.66</td>
</tr>
<tr>
<td>DASS – stress</td>
<td>6.83</td>
<td>0.93</td>
</tr>
<tr>
<td>PRMQ</td>
<td>39.1</td>
<td>1.1</td>
</tr>
</tbody>
</table>

SF-36, 36-item Short Form Health Survey; DASS, Depression Anxiety Stress Scales; PRMQ, Prospective and Retrospective Memory Questionnaire.

* P values for time × treatment interaction terms determined by repeated-measures ANCOVA, adjusting for age, sex, years of education and APOE ε4 allele carriage.

Table 3. Adjusted marginal means of cognitive measures at all time points for the treatment group and placebo group (Mean values and standard deviations)

<table>
<thead>
<tr>
<th></th>
<th>Placebo group</th>
<th>Curcumin group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>6 months</td>
</tr>
<tr>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>MoCA</td>
<td>26.4</td>
<td>0.3</td>
</tr>
<tr>
<td>RAVLT list A trial 1–5 total</td>
<td>46.2</td>
<td>1.1</td>
</tr>
<tr>
<td>RAVLT short-term recall</td>
<td>9.5</td>
<td>0.3</td>
</tr>
<tr>
<td>RAVLT delayed recall</td>
<td>8.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Wechsler Digit Symbol Scale</td>
<td>49.3</td>
<td>1.2</td>
</tr>
<tr>
<td>COWAT</td>
<td>44.3</td>
<td>1.7</td>
</tr>
<tr>
<td>Non-computerised composite score</td>
<td>0.001</td>
<td>0.09</td>
</tr>
<tr>
<td>Computerised composite score</td>
<td>−0.04</td>
<td>0.05</td>
</tr>
</tbody>
</table>

MoCA, Montreal Cognitive Assessment; RAVLT, Rey Auditory Verbal Learning Test; COWAT, Controlled Oral Word Association Task.

* P values for time × treatment interaction terms determined by repeated-measures ANCOVA, adjusting for age, sex, years of education and APOE ε4 allele carriage.

![Fig. 2. Adjusted marginal means of Montreal Cognitive Assessment (MoCA) scores (adjusted for age, sex, years of education and APOE ε4 allele carriage) for both groups at each study time point. Baseline MoCA performance was significantly different between the two groups (P < 0.05). A significant interaction of time × treatment group for MoCA scores was also observed (P < 0.05).](image)

placebo group at the 6-month follow-up that was not observed in the curcumin treatment group. No differences were observed between the treatment groups in all other clinical and cognitive measures.

A large body of animal studies supports the hypothesis that curcumin is beneficial for cognitive health. A paucity of evidence is present, however, to support the proposed beneficial effect of curcumin on cognition in humans. In the present study, we found no between-treatment group differences in measures of cognition over 12 months. Nevertheless, a decrease in MoCA performance (used to assess general cognitive function) at the 6-month follow-up compared with baseline was observed in the placebo group, which did not manifest in the curcumin treatment group, contributing to a significant time × treatment interaction. Furthermore, at baseline, the placebo group performed significantly better on the MoCA than the curcumin group; however, at 12 months, the MoCA score of both groups was equivalent. Our results differ from a recent study by Cox et al., who reported a beneficial effect of acute (1 h after single dose) and chronic (4-week treatment) curcumin treatment on working memory. It should be noted that the effect of curcumin on cognition after 4 weeks of treatment was trend level (unadjusted, reaching significance after adjustment), and that only one task (not administered in the current study), out of a number of cognitive tasks assessed, was shown to be influenced by curcumin treatment. The authors attribute the acute positive effect of curcumin to an up-regulation of monoaminergic neurotransmission. It is possible that short-term effects of curcumin on cognition may indeed be due to increased levels of neurotransmitters; however, whether such
transmitter up-regulation can be maintained chronically requires further investigation. Divergent methodologies, most notably, study duration and use of different curcumin formulations, between the present study and that of Cox et al. may account for the differing results.

In the present study, we hypothesised that curcumin would have an effect on attenuating cognitive decline, rather than a direct effect on improving cognitive function. Nevertheless, in our highly educated cohort, we observed little cognitive decline on any tasks in either the placebo or the treatment group. Even though the cognitive battery was carefully selected to assess numerous cognitive functions including global cognition, episodic verbal memory, executive function, working memory and attention, and verbal fluency, it is possible that the magnitude of change exhibited by our high-functioning cohort was too small to be detected. The cognitive performance of our cohort over the follow-up period is, however, consistent with previous reports of a cognitively healthy cohort demonstrating a lack of cognitive decline over 12 months(43). In an attempt to gain a greater understanding of the effect of curcumin on cognition, future studies should consider longer intervention duration than that used in the present study. Furthermore, with longer periods of follow-up or with investigation of an even older cohort at increased risk of cognitive decline, the effect of curcumin treatment on cognition may be more pronounced. Such approaches would also facilitate examination of the effect of curcumin therapy on rate of conversion to mild cognitive impairment or AD, and are feasible considering the excellent safety profile and general tolerability of the curcumin formulation utilised.

A number of animal and human studies indicate that curcumin has a positive effect on symptoms of depression and anxiety(34–40). In the present study, however, curcumin was not shown to influence self-reported measures of depressive and anxiety-related symptoms over 12 months; this result is not entirely unexpected, given that individuals with current depressive symptoms were excluded from the study. Although the majority of human studies yielding positive results in the context of depression and anxiety symptoms were conducted on individuals with major depressive disorder(34–40), one study showed an improvement in self-reports of mood among non-depressed individuals, after a 4-week curcumin intervention(24).

Bioavailability is an important consideration in studies of curcumin supplementation. Poor absorption of orally administered curcumin as well as rapid metabolism in the intestine and liver have long been identified as limitations of curcumin therapy. Thus, a great deal of research activity has focused on the development of formulations, which are more readily absorbed and yield increased levels of curcumin in its unconjugated form. The varying pharmacokinetics of different curcumin formulations likely contributes to the heterogeneity of results among studies of curcumin in humans. Indeed, Ringman et al.(23) were unable to determine whether the lack of efficacy observed following Curcumin C3 Complex® (Sabinsa Corporation) administration was due to inefficacy of curcumin as an AD intervention or due to limited bioavailability of the formulation as evidenced by biochemical analysis of blood and cerebrospinal fluid samples. Cox et al.(24) utilised Longvida® Optimized Curcumin in their investigation of the effect of curcumin on cognition and mood in healthy older adults; in contrast, the present study utilised Biocurcumax™. Both the Longvida® and Biocurcumax™ formulations are reported to reach plasma concentrations of free curcumin, which are significantly greater than that of unformulated curcumin; there are, however, between-formulation differences in pharmacokinetic parameters such as reported peak plasma concentration, time to peak concentration and elimination rate(25,28). The curcumin formulation, dosage and frequency of administration are all likely to have impacted the results of the present and previous studies. It is also important to note that the therapeutic concentration of curcumin with regard to enhancing cognition requires further investigation. Although previous reports from Cox et al. describe a positive effect of a daily dose of 400 mg of the Longvida® formulation on cognition, more research in larger cohorts with longer intervention periods is required to identify a therapeutic dose. The three times daily 500 mg Biocurcumax™ dose utilised in the present study to sustain optimum curcumin blood levels may have also impacted upon intervention compliance and tolerability, contributing to the number of gastrointestinal-related adverse events and subsequent participant withdrawal from the study. Nevertheless, it is unclear whether the high adverse event rate was due to the nature of the Biocurcumax™ formulation or curcumin itself. At study commencement, participants were blinded to curcumin consumption; steady increase to the eventual Biocurcumax™ daily dose would have likely reduced the number of participant withdrawals. Indeed, we are currently using this incremental Biocurcumax™ dosage approach as part of a sister study investigating the role of curcumin in preventing AD (ANZCTR identification number: ACTRN12613000681752), with excellent intervention tolerability observed to date.

Although the results of the present study indicate that, in this cohort of cognitively normal older adults, curcumin had limited influence on cognitive function, mood or general quality of life over 12 months, it is important to note that alterations in cognition manifest up to 20 years after the commencement of AD-related neuropathological changes. Furthermore, other studies have demonstrated positive effects of curcumin on Aβ, tau, inflammation and oxidative stress – factors well known to be associated with AD pathogenesis and pathology(4,7–9). Thus, additional longitudinal studies, which include measurement of biological markers of AD pathology, are warranted, in order to fully elucidate the ability of curcumin to slow neurodegeneration leading to cognitive decline and AD.

Acknowledgements

The authors thank all those who participated in the study for their commitment and dedication to help advance Alzheimer’s disease research. The authors also thank the following individuals for their contribution to the study: Dr Roger Clarnette (medical oversight), Assistant Professor Michael Weinborn (QC of neuropsychological test scores), Assistant Professor Simon Laws and Tenielle Porter (APOE genotyping), Research Assistants, Shaun Markovic, Kerry McCabe, Ellen
Putland, Georgia Martins, and Researchers, Dr Sajla Singh, and Dr Cynthia Gregory (neuropsychological test administration and blood sample processing).

This work was funded by the McCusker Alzheimer’s Research Foundation, and a grant awarded to SRS, KGG, and RNM by the Hollywood Private Hospital Research Foundation (grant no. RF062). HRS is supported by the Australian CRC for Mental Health Programme. CogState Limited, Melbourne, Victoria, Australia, provided the computerised cognitive assessment battery utilised in this study free of charge. BiocurcumaxTM and placebo capsules were provided free of charge by Arjuna Natural Extracts Limited, Kerala, India. Arjuna Natural Extracts Limited and CogState Limited had no role in the design, analysis, or writing of this article.

R. N. M. and H. R. S. designed the study; S. R. R.-S., B. M. B., H. R. S. and T. S. conducted the study; S. R. R.-S., B. M. B. and H. R. S. analysed the data; S. R. R.-S., B. M. B., H. R. S., K. G. G., V. B. G. and R. N. M. wrote the paper; R. N. M. had primary responsibility for final content; and all the authors have read and approved the final version of the manuscript.

The authors declare that there are no conflicts of interest.

References